J&J Drug, Nipocalimab, Shows Positive Results on Phase 2/3 Study
Johnson & Johnson announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChR-positive adolescents (ages 12–17) with generalized myasthenia gravis (gMG). Participants receiving nipocalimab plus standard care showed sustained disease control, meeting the primary endpoint of IgG reduction over 24 weeks, along with improvements in MG-ADL and QMG scores. These findings will be highlighted in an oral presentation at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the AANEM Annual Meeting.
J&J Drug, Nipocalimab, Shows Positive Results on Phase 2/3 Study